Molecular monitoring during dose reduction predicts recurrence after TKI cessation in CML

Research output: Contribution to journal › Research article › Contributed › peer-review

Contributors

Details

Original languageEnglish
Pages (from-to)766-769
Number of pages4
JournalBlood
Volume135
Issue number10
Publication statusPublished - 5 Mar 2020
Peer-reviewedYes

External IDs

Scopus 85081944328
ORCID /0000-0002-2524-1199/work/142251505
ORCID /0000-0002-6741-0608/work/199962863

Keywords

Keywords

  • Clinical Trials as Topic/methods, Dose-Response Relationship, Drug, Drug Monitoring/methods, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis, Molecular Diagnostic Techniques, Prognosis, Progression-Free Survival, Protein Kinase Inhibitors/administration & dosage, Recurrence, Remission Induction, Withholding Treatment

Library keywords